![ATAGI statement on the Omicron variant and timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care ATAGI statement on the Omicron variant and timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/images/news/2021/12/atagi-statement-on-the-omicron-variant-and-timing-of-covid-19-booster-vaccination.jpeg)
ATAGI statement on the Omicron variant and timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care
![Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority ... Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority ...](https://www.thelancet.com/cms/attachment/0e44cfd8-feec-43db-ba26-b407245bde92/gr1.jpg)
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority ...
![Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study - eClinicalMedicine Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study - eClinicalMedicine](https://www.thelancet.com/cms/attachment/f319102b-6a4a-4d84-bef1-7cb2e4b7a481/gr1.jpg)
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study - eClinicalMedicine
![COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7104e2_IncidenceDeathRatesOmicron_IMAGE_21Jan22_1200x627.jpg?_=64029)
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR
![ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/images/news/2021/12/atagi-statement-on-the-omicron-variant-and-the-timing-of-covid-19-booster-vaccination.jpeg)